Literature DB >> 9708428

Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team.

M J Gill.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708428

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

1.  Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.

Authors:  J M Kilby; G Sfakianos; N Gizzi; P Siemon-Hryczyk; E Ehrensing; C Oo; N Buss; M S Saag
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.

Authors:  N Buss; P Snell; J Bock; A Hsu; K Jorga
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 3.  A risk-benefit assessment of HIV protease inhibitors.

Authors:  G J Moyle; B G Gazzard
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

Review 4.  Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.

Authors:  D P Figgitt; G L Plosker
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 5.  Saquinavir: a review of its use in boosted regimens for treating HIV infection.

Authors:  Greg L Plosker; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Saquinavir soft gelatin capsule: a comparative safety review.

Authors:  J Gill; J Feinberg
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.